000739SZSE

Progress Announcement on Guarantees for Subsidiaries

Apeloa Pharmaceutical Co., Ltd.··5 pages

✨ AI Summary

This announcement details the guarantees provided by ProLog Pharma Co., Ltd. for its subsidiaries, totaling up to 1.1 billion RMB. Key guarantees include 100 million RMB for Shandong ProLog Debang Pharmaceutical Co., Ltd. and 20 million RMB for Shandong ProLog Hanxing Pharmaceutical Co., Ltd. The board confirms that these guarantees align with the company's operational needs and pose no significant financial risks. The total guarantee balance now stands at 3.82348 billion RMB, representing 60.32% of the audited net assets for 2025.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Overview of Guarantees

  1. On March 13, 2026, ProLog Pharma Co., Ltd. (hereinafter referred to as "the Company") signed a "Maximum Guarantee Contract" (Contract No. 2026 Changyi General Guarantee No. 005) with the Changyi Branch of Bank of China, agreeing to provide a joint liability guarantee of up to 100 million RMB for its wholly-owned subsidiary, Shandong ProLog Debang Pharmaceutical Co., Ltd., with a guarantee period of three years.
  2. On March 23, 2026, the Company signed an "Irrevocable Guarantee Letter" (Contract No. 571HT260319T00032101) with the Jinhua Yiwu Branch of China Merchants Bank, agreeing to provide a joint liability guarantee for a working capital loan of 10 million RMB for its wholly-owned subsidiary, Zhejiang ProLog Jiayuan Pharmaceutical Co., Ltd., under the "Loan Contract" (Contract No. 571HT260319T000321) for a period of 12 months.
  3. On March 24, 2026, the Company signed a "Guarantee Contract" (Contract No. Hengdian 2026 Renbao No. 072) with the Dongyang Branch of Bank of China, agreeing to provide a joint liability guarantee for a bank acceptance bill of 15 million RMB for its holding subsidiary, Zhejiang ProLog Kangyu Pharmaceutical Co., Ltd., under the "Commercial Acceptance Bill Acceptance Agreement" (Contract No. Hengdian 2026 Rencheng No. 072) for a period of 6 months.
  4. On March 26, 2026, the Company signed a "Guarantee Contract" (Contract No. Hengdian 2026 Renbao No. 070) with the Dongyang Branch of Bank of China, agreeing to provide a joint liability guarantee for a working capital loan of 20 million RMB for its wholly-owned subsidiary, Shandong ProLog Hanxing Pharmaceutical Co., Ltd., under the "Working Capital Loan Contract" (Contract No. Hengdian 2026 Renjiao No. 070) for a period of 12 months.

Review Procedures for Guarantee Matters

The Company held meetings on March 7, 2025, and April 17, 2025, during which the 9th Board of Directors and all members confirmed that the information disclosed regarding the guarantees is true, accurate, and complete, with no false records, misleading statements, or significant omissions. The proposal for providing guarantees for 10 subsidiaries and sub-subsidiaries, with a total financing guarantee of no more than 7.1 billion RMB from banks and other financial institutions, was approved at the annual shareholders' meeting in 2024. The authorization period for external guarantees is from the date of approval at the 2024 annual shareholders' meeting until the date of the 2025 annual shareholders' meeting. Specific details can be found in the announcements published on March 11, 2025, and April 18, 2025, in the "Securities Times" and on the Giant Tide Information Network.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing